Quantcast
Last updated on April 17, 2014 at 9:26 EDT

Latest Columbia Laboratories Inc. Stories

2014-04-15 04:20:53

NOTTINGHAM, England, April 15, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales. The development and manufacturing services provider, which has a well-established track record for meeting objectives while tightening development timelines for its clients, has hired...

2014-04-08 04:21:42

NOTTINGHAM, England, April 8, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficult-to-progress molecules. The UK-based pharmaceutical development and manufacturing services provider has invested in GMP hot melt extrusion (HME) technology along with further milling...

2014-03-07 08:25:14

BOSTON, March 7, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding...

2014-03-05 08:28:24

BOSTON, March 5, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the three- and twelve-month periods ended December 31, 2013. Financial highlights for the fourth quarter of 2013: -- Total net revenues grew 10% to $7.8 million compared to $7.1 million in the fourth quarter of 2012. -- GAAP income from operations was $0.8 million compared to $1.0 million in the fourth quarter of 2012. -- GAAP diluted earnings...

2014-03-03 08:30:41

BOSTON, Mar. 3, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors. Mr. Hunter qualifies as a financial expert under the SEC guidelines, and will serve on the Company's audit committee. "Donald Hunter brings a wealth of experience in accounting and control, financial reporting, mergers and...

2014-02-26 08:27:54

BOSTON, Feb. 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Wednesday, March 5, 2014 Time: 8:30...

2014-02-19 20:22:04

- Financial Statements Understated Net Income Due to Calculation Error - BOSTON, Feb. 19, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced a restatement of its previously-issued unaudited interim consolidated financial statements for the three- and nine-month periods ended September 30, 2013 due to a calculation error related to its common stock warrant expense, a non-cash item, for these periods. Following a review of the financial statements, the Company...

2014-02-04 08:33:45

BOSTON, Feb. 4, 2014 /PRNewswire/ -- Frank Condella, President and Chief Executive Officer of Columbia Laboratories Inc. (Nasdaq: CBRX) will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference. The presentation is scheduled as follows: Date: Tuesday, February 11, 2014 Time: 9:30 a.m. Eastern Time Location: The Waldorf Astoria, New York City Live Webcast:...

2014-01-09 08:26:30

Revenue Growth of 12%-14% Expected Year-over-Year BOSTON, Jan. 9, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced preliminary, unaudited financial results of the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, the Company expects to report: -- Total revenues in the range of $7.4 to $8.0 million, as compared with $7.1 million in the fourth quarter of 2012. -- Services revenues from Molecular Profiles in the...

2013-11-14 08:32:29

Columbia Retains Royalty Right on U.S. CRINONE Sales BOSTON, Nov. 14, 2013 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into an agreement with Actavis, Inc. ("Actavis") for early termination of the companies' current exclusive Supply Agreement for CRINONE(®) (progesterone gel). The exclusive Supply Agreement, which would have otherwise terminated in May 2015, provided for Columbia to receive a 10% mark-up on its cost of goods of all product sold to...